地西他滨+CAG与HAG治疗老年初治急性髓性白血病的对比研究

摘要

Objective To evaluate and compare the efficacy and toxicity of priming induction regimen of decitabine+CAG and HAG in the treatment for newly diagnosed acute myeloid leukemia(AML) in elderly patients.Methods Forty-five patients were divided into two groups:twenty-three elderly patients with AML were treated with priming induction regimen of decitabine+CAG, and twenty-two elderly patients with AML were treated with priming induction regimen of HAG.Patients in decitabine+CAG group had an intermission of three weeks between two courses of chemotherapy.Patients in HAG group had an intermission of two weeks two courses of chemotherapy.Results The complete remission rate in decitabine+CAG group was78.3%,the total effective rate was 95.7%,and the complete remission rate in HAG group was 54.5%,the total effective rate was 77.3%.There were no significant differences in total effective rate between the two groups.And the side effects between the two groups were of no significant difference.Conclusions The priming induction regimens of decitabine+CAG has higher complete remission rate and effective rate, high chemotherapy intensity and are more sensitive to chemotherapeutic drugs with no more side effects.It can be recommended for use in newly diagnosed AML of elderly patients.%目的 评价地西他滨+CAG方案及HAG方案治疗老年初治急性髓性白血病(AML)的疗效及不良反应. 方法 45例老年初治AML分为地西他滨+CAG治疗组及HAG治疗组,23例病人予以地西他滨+CAG方案治疗,22例病人予以HAG治疗,地西他滨+CAG治疗组病人在第1疗程后间歇21 d左右进行第2个疗程;HAG治疗组病人在第1疗程后间歇14 d左右进行第2个疗程,评价并比较2组疗效及不良反应. 结果 地西他滨+CAG治疗组的完全缓解(CR)率为78.3%,总有效率为95.7%;HAG治疗组CR率为54.5%,总有效率达为77.3%,2组比较差异无统计学意义.2组血液系统不良反应比较差异无统计学意义. 结论 地西他滨+CAG方案CR率及有效率与HAG方案相当、没有更多的不良反应,化疗强度,敏感性更大,在老年初治AML病人中值得推荐应用.